NVIDIA entered a collaboration with Simulations Plus to apply GPU acceleration and AI-assisted workflows to drug development and quantitative systems pharmacology (the study of how drugs move through and affect the body).
The partnership targets complex modeling and simulation tasks in early-stage drug discovery, with GPU-optimized workflows for physiologically based pharmacokinetics and quantitative systems pharmacology potentially cutting end-to-end modeling times by up to 75% in testing.
NVIDIA extends its life sciences presence through this specialist software provider, whose tools are already used in pharmaceutical R&D, while the move complements existing partnerships with IREN and Corning on AI infrastructure.
Summaries like this, in your inbox every morning.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Chunghwa Telecom president Rong-shy Lin said the shift from conversational AI to autonomous AI agents is resha…
CoreWeave fell 5% in premarket trading Friday and was on track to finish the week down 15%, after rebounding f…
Apple and Meta said they would jointly release a new open-weight AI model designed to run on high-end Macs, ai…
Investors put $38.5 billion into Asian startups in Q3, per Crunchbase data
A longtime Anthropic investor told Fortune he expects shares priced around $1.8 trillion, below the company's…
In Q2, billionaires or their funds sold six 'Magnificent Seven' AI stocks
